Trials / Unknown
UnknownNCT01801852
Autologous Natural Killer T Cells Infusion for the Treatment of Cancer
Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and effectiveness of natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast cancer, glioma, hepatocellular carcinoma, squamous cell lung cancer, pancreatic cancer, colon cancer or prostate cancer.
Detailed description
A randomized controlled trial on the efficacy and safety of autologous natural killer T (NKT) cells infusion treatment in advanced cancer.
Conditions
- Breast Cancer
- Glioma
- Hepatocellular Cancer
- Squamous Cell Lung Cancer
- Pancreatic Cancer
- Colon Cancer
- Prostate Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | NKT cells |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2016-05-01
- Completion
- 2017-06-01
- First posted
- 2013-03-01
- Last updated
- 2016-01-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01801852. Inclusion in this directory is not an endorsement.